Erdafitinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 3 mg, 4 mg, 5 mg
Reference Brands: Balversa (USA)
Category:
Oncology Cancer Care
Erdafitinib is available in Tablets
and strengths such as 3 mg, 4 mg, 5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Erdafitinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Erdafitinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Erdafitinib, marketed under the brand name Balversa, is an oral anti-cancer medication and a small-molecule inhibitor of fibroblast growth factor receptors (FGFRs). FGFRs are a subset of tyrosine kinases that, when unregulated, contribute to tumor cell proliferation, differentiation, angiogenesis, and survival. By selectively inhibiting FGFR activity, erdafitinib interferes with these processes, helping to slow or stop the growth of cancer cells that rely on FGFR signaling.
Erdafitinib is specifically indicated in the United States for the treatment of adults with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 genetic alterations, particularly in patients whose disease has progressed following at least one prior systemic therapy. Developed initially by Astex Pharmaceuticals and licensed to Janssen Pharmaceuticals for further clinical development, erdafitinib represents a precision oncology therapy targeting tumors with defined genetic profiles. Its oral administration and targeted mechanism of action provide a convenient and effective treatment option for patients with FGFR-driven malignancies, offering a personalized approach to cancer management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing